Lysols are being sold to patients at a rate of 10 per cent per month, which would amount to a profit of up to €3.5 million a year, according to the company’s CEO, Luca Dei.
Dei was speaking at a media briefing at the Lydian Hotel in Barcelona on Monday.
“I think the real story is that it is a very small company, and we are not a bank.
This is just one of the things we are doing.
There are a lot of things we need to do, and that’s why we are going to continue to do this.
It’s not just a company that is struggling to meet its revenue targets, it’s a company which needs to be supported, which needs an additional income stream, and which has an ongoing challenge with the health system,” Dei said.
Dei did not provide any numbers, but said the company would be in a better position if it sold more products.
Lysols have faced a string of scandals, from the leak of confidential patient data in 2015, to the sale of a patient-only treatment centre to a private company in 2017, where they had a financial relationship with the government.
The company has said it will never sell the medicine to anyone who is under 18, and its products are only sold to the terminally ill.
The situation has put a strain on Lysools finances.
Last year, the company made a €10 million loss, but Dei promised the financial picture would improve.
‘The government’s reaction is the only thing that matters’ “The government has been very supportive.
I am proud of what they have done, and what they are doing with the healthcare sector, and I am even more proud of the fact that our people are able to continue the work that they have been doing for us for more than 30 years.
That’s the only reason I’m here, to be here and support the work we are trying to do,” Deidi said on Monday evening.
Meanwhile, a new government bill would allow doctors to dispense Lysool under a new category called ‘medicinal cannabis’ under the Medicines and Healthcare Products Regulatory Agency (MHRA).
The new category would cover only products that have a THC level of 0.5 per cent or less, with no more than a 0.3 per cent THC content, as well as products with a CBD level between 0.7 and 1 per cent, with up to 0.2 per cent CBD content.
MHRA would be able to make decisions about whether or not to approve products.
“The new regulatory framework has been designed to allow for the rapid development of medicinal cannabis products and to allow the health sector to continue developing their own products that meet the needs of their patients,” a spokesperson for the MHRA said.